What does this research mean for the field?

Surufatinib demonstrates preliminary antitumor activity and a manageable safety profile as a second-line or further treatment for advanced sarcoma, yielding a 12-week progression-free rate of 71.1%. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of surufatinib, a VEGFR, FGFR, and CSF-1R inhibitor, as second-line or subsequent therapy in patients with advanced, treatment-refractory sarcoma.

August 27, 2026BMC MedicineOpen Access

Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

BXBushu XuSun Yat-sen University 潘潘秋中Sun Yat-sen University SLShining LiXinjiang University

Discussion

Member takes

Implication

Phase 2 trial demonstrates antitumor activity and manageable safety of surufatinib in advanced sarcoma, indicating its potential in second-line treatment.

Key Points

To evaluate the efficacy and safety of surufatinib, a VEGFR, FGFR, and CSF-1R inhibitor, as second-line or subsequent therapy in patients with advanced, treatment-refractory sarcoma.
Multicenter, single-arm, phase 2 trial (NCT05106777) evaluating once-daily oral surufatinib (300 mg) in 47 enrolled patients with unresectable or metastatic sarcoma after prior therapy failure.
Assessed the primary endpoint of 12-week progression-free rate alongside secondary endpoints including objective response rate, disease control rate, progression-free survival, and overall survival across a median follow-up of 27.5 months.
Among 45 evaluable patients, the 12-week progression-free rate was 71.1%, the objective response rate was 11.1%, the disease control rate was 86.7%, and median progression-free survival was 4.3 months.
Progression-free survival was significantly longer in the second-line setting than in later lines (median 5.7 vs. 2.8 months; p < 0.001) and in non-uterine leiomyosarcoma (median 7.2 vs. 4.2 months; p = 0.024).
Median overall survival was not reached (1-year OS 82.2%; 2-year OS 63.9%), with grade ≥3 treatment-related adverse events occurring in 29.8% of patients.

Cite This Study

Xu et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe9b910c91c1e92621925 https://doi.org/10.1186/s12916-026-05154-7

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial demonstrates antitumor activity and manageable safety of surufatinib in advanced sarcoma, indicating its potential in second-line treatment.

Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider